161 related articles for article (PubMed ID: 22543627)
1. Familial Mediterranean fever: risk factors, causes of death, and prognosis in the colchicine era.
Akar S; Yuksel F; Tunca M; Soysal O; Solmaz D; Gerdan V; Celik A; Sen G; Onen F; Akkoc N
Medicine (Baltimore); 2012 May; 91(3):131-136. PubMed ID: 22543627
[TBL] [Abstract][Full Text] [Related]
2. Familial Mediterranean fever in childhood: a single-center experience.
Barut K; Sahin S; Adrovic A; Sinoplu AB; Yucel G; Pamuk G; Aydın AK; Dasdemir S; Turanlı ET; Buyru N; Kasapcopur O
Rheumatol Int; 2018 Jan; 38(1):67-74. PubMed ID: 28828621
[TBL] [Abstract][Full Text] [Related]
3. Familial Mediterranean Fever-Related Amyloidosis in Turkey: A Need for a Familial Mediterranean Fever Registry.
Helvaci O; Yasar E
Exp Clin Transplant; 2023 Jun; 21(Suppl 2):101-104. PubMed ID: 37496356
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
[TBL] [Abstract][Full Text] [Related]
5. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis.
Saatçi U; Ozen S; Ozdemir S; Bakkaloglu A; Besbas N; Topaloglu R; Arslan S
Eur J Pediatr; 1997 Aug; 156(8):619-23. PubMed ID: 9266193
[TBL] [Abstract][Full Text] [Related]
6. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
Sargin G; Kose R; Senturk T
Sao Paulo Med J; 2019 May; 137(1):39-44. PubMed ID: 31116269
[TBL] [Abstract][Full Text] [Related]
7. Non-response to colchicine in familial Mediterranean fever should be identified accurately.
Melikoglu MA; Senel K
Int J Rheum Dis; 2017 Dec; 20(12):2118-2121. PubMed ID: 24702830
[TBL] [Abstract][Full Text] [Related]
8. Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents.
Twig G; Livneh A; Vivante A; Afek A; Shamiss A; Derazne E; Tzur D; Ben-Zvi I; Tirosh A; Barchana M; Shohat T; Golan E; Amital H
Ann Rheum Dis; 2014 Apr; 73(4):704-9. PubMed ID: 23505237
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of renal transplantation in patients with familial Mediterranean fever amyloidosis: a single-center experience.
Abedi AS; Nakhjavani JM; Etemadi J
Transplant Proc; 2013; 45(10):3502-4. PubMed ID: 24314942
[TBL] [Abstract][Full Text] [Related]
10. [Fever of unknown origin and colchicine-sensitive amyloidosis: familial Mediterranean fever?].
Schneider W; Wehmeier A
Dtsch Med Wochenschr; 1989 Jun; 114(24):951-4. PubMed ID: 2731480
[TBL] [Abstract][Full Text] [Related]
11. Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever.
Tekgöz E; Çolak S; Çınar Fİ; Yılmaz S; Çınar M
Turk J Med Sci; 2021 Oct; 51(5):2357-2363. PubMed ID: 33957721
[TBL] [Abstract][Full Text] [Related]
12. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study.
Medicine (Baltimore); 2005 Jan; 84(1):1-11. PubMed ID: 15643295
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and survival in AA amyloidosis patients.
Ayar Y; Ersoy A; Oksuz MF; Ocakoglu G; Vuruskan BA; Yildiz A; Isiktas E; Oruc A; Celikci S; Arslan I; Sahin AB; Güllülü M
Rev Bras Reumatol Engl Ed; 2017; 57(6):535-544. PubMed ID: 29173691
[TBL] [Abstract][Full Text] [Related]
14. Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia.
Bilgin E; Dizdar Ö; Güven DC; Ceylan S; Aybi Ö; Fırlatan B; Kardaş RC; Yıldırım T; Hayran MK; Kalyoncu U; Özen S
Rheumatol Int; 2019 Jun; 39(6):1045-1051. PubMed ID: 31025139
[TBL] [Abstract][Full Text] [Related]
15. [Familial Mediterranean fever: not to be missed].
Frenkel J; Bemelman FJ; Potter van Loon BJ; Simon A
Ned Tijdschr Geneeskd; 2013; 157(18):A5784. PubMed ID: 23635502
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of kidney transplantation in patients with familial mediterranean fever.
Bitik B; Hatipoğlu B; Sayın B; Kanbur AY; Bursa N; Oygur CŞ; Özdemir H; Colak T; Haberal M; Yücel AE
Clin Transplant; 2023 Feb; 37(2):e14888. PubMed ID: 36544375
[TBL] [Abstract][Full Text] [Related]
17. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years.
Ben-Chetrit E; Levy M
Semin Arthritis Rheum; 1991 Feb; 20(4):241-6. PubMed ID: 2042056
[TBL] [Abstract][Full Text] [Related]
18. Familial Mediterranean fever-associated infertility and underlying factors.
Atas N; Armagan B; Bodakci E; Satis H; Sari A; Bilge NSY; Salman RB; Yardımcı GK; Babaoglu H; Kilic L; Ozturk MA; Goker B; Haznedaroglu S; Kasifoglu T; Kalyoncu U; Tufan A
Clin Rheumatol; 2020 Jan; 39(1):255-261. PubMed ID: 31502094
[TBL] [Abstract][Full Text] [Related]
19. Biological agents in familial Mediterranean fever focusing on colchicine resistance and amyloidosis.
Sozeri B; Kasapcopur O
Curr Med Chem; 2015; 22(16):1986-91. PubMed ID: 25760087
[TBL] [Abstract][Full Text] [Related]
20. Canakinumab treatment in children with familial Mediterranean fever: report from a single center.
Yazılıtaş F; Aydoğ Ö; Özlü SG; Çakıcı EK; Güngör T; Eroğlu FK; Gür G; Bülbül M
Rheumatol Int; 2018 May; 38(5):879-885. PubMed ID: 29450637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
